⌕
Endovia Health Sciences · EDVA · NYSE
Tenet 5 · Weak
Compare
$0.14−10.04%At closeTenet 5 · Weak
$0.14−0.02 (−10.04%)
At close: Nov 19, 2026, 4:00 PM ET· NYSE · USD

Endovia Health Sciences (EDVA) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 100% below its peak, net margin −34537.0%.
The four lines that matter · FY21–FY25
Revenue ($K)▼90.9%
73.1
FY21→FY25CAGR −71.7%/yr
Net income ($K)▼6.2%
−25,234.8
FY21→FY25CAGR —
Free cash flow ($K)▲34.0%
−4,820.0
FY21→FY25CAGR —
Diluted EPS▲32.3%
−11.97
no value for 2 of 5 yearsCAGR —
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)73.1Revenue56.2COGS16.9Gross profit−2907.2SG&A−14186.2Op income−11048.6Tax & other−25234.8Net income

-34537¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
403020100%sector median net margin ~4%FY21FY25

Over this window: gross 34.6% → 23.1%. Net margin -34537.0% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7108, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
8.773.1801.318,850.218,087.511,316.0▼90.9%−71.7%
Cost of revenue
−96.9−56.2921.113,281.512,168.67,398.2——
Gross profit
−6.816.9−119.85,568.75,918.93,917.8—−74.4%
Selling, general & admin
2,785.82,907.24,027.812,188.612,917.310,009.9▼27.8%−26.6%
Total operating expenses
14,006.514,203.19,781.520,855.427,313.533,000.7▲45.2%−19.0%
Operating incomefeeds ROC rank
−14,012.3−14,186.2−9,900.4−15,286.7−21,394.6−29,082.9▼43.3%—
Other income, net
−2,945.5−10,163.1−7,610.0−5,717.1−245.4−262.4——
Pretax income
−16,957.8−24,349.3−17,510.4−21,003.8−21,640.1−29,345.4▼39.1%—
Income tax
—0.00.00.00.00.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−17,282.6−25,234.8−23,756.6−26,720.9−22,084.6−29,050.8▼6.2%—
Per share
Diluted EPSbuyback-sensitive
−4.86−11.97−17.68−25.18c——▲32.3%—
Diluted shares (mn)
3.062.181.341.06——▲62.8%+43.3%
Margins
Gross margin27th pct in Consumer Defensive
−78.3%23.1%−15.0%29.5%32.7%34.6%▲38.1pp−11.5pp
Operating margin
−161357.2%−19415.6%−1235.6%−81.1%−118.3%−257.0%▼18180.0pp−19158.6pp
Net margin0th pct in Consumer Defensive
−199016.1%−34537.0%−2964.9%−141.8%−122.1%−256.7%▼31572.2pp−34280.3pp
† TTM = trailing four quarters through 2026-06-30.c Computed by Tenet. The company's diluted figure is not in our data feed for this period, so this is net income attributable to common shareholders divided by the larger of the weighted basic and diluted share counts.
FY11 – FY20 · 10 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 10 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-04-15 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Endovia Health Sciences' revenue last fiscal year?

Endovia Health Sciences reported revenue of $73.1K in fiscal 2025, down 90.9% from fiscal 2024.

What was Endovia Health Sciences' net income?

Endovia Health Sciences reported net income of −$25,234.8K in fiscal 2025, a net margin of −34537.0%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.